Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) traded down 3.6% during trading on Wednesday . The stock traded as low as $11.77 and last traded at $11.81, with a volume of 182,974 shares trading hands. The stock had previously closed at $12.25.

Several analysts have recently commented on the company. Mizuho cut Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price target for the company. in a report on Thursday, August 4th. Jefferies Group reduced their price target on Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating for the company in a report on Thursday, August 4th. Zacks Investment Research raised Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday. Maxim Group reduced their price target on Sucampo Pharmaceuticals from $26.00 to $17.00 and set a “buy” rating for the company in a report on Monday, August 1st. Finally, Roth Capital reissued a “buy” rating on shares of Sucampo Pharmaceuticals in a report on Wednesday, April 20th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $19.67.

The company’s 50 day moving average price is $11.38 and its 200 day moving average price is $11.59. The firm has a market capitalization of $506.44 million and a price-to-earnings ratio of 41.51.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The business earned $52 million during the quarter, compared to the consensus estimate of $48.33 million. During the same period last year, the company earned $0.21 earnings per share. The business’s quarterly revenue was up 49.1% compared to the same quarter last year. On average, analysts expect that Sucampo Pharmaceuticals Inc. will post $1.02 EPS for the current year.

An institutional investor recently raised its position in Sucampo Pharmaceuticals stock. Globeflex Capital L P raised its position in Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) by 76.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,588 shares of the biopharmaceutical company’s stock after buying an additional 28,431 shares during the period. Globeflex Capital L P owned approximately 0.15% of Sucampo Pharmaceuticals worth $1,134,000 as of its most recent filing with the SEC.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.